Latest Regulatory Milestones News

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

TG Metals has completed the acquisition of an 80% stake in the Van Uden Gold Project, updated its mineral resource estimate to JORC 2012 standards, and begun drilling historical stockpiles with initial assay results received.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

Lithium Plus Minerals reports significant progress on its Lei Lithium Development Project alongside promising discoveries of beryllium and gold at its Arunta and Wingate projects, supported by a solid cash position of A$3.2 million.

Akora Resources has renewed its key Bekisopa exploration tenement and appointed Peter Bird as CEO, strengthening its path toward developing a high-grade iron ore mine in Madagascar. The project enjoys strong local and government support amid infrastructure upgrades.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Power Minerals Limited has completed a significant drilling program at its Santa Anna Project in Brazil, confirming robust niobium and rare earth element mineralisation. The company also progressed its Rincon Lithium JV in Argentina and secured nearly A$3.9 million in new funding to support exploration and development.

QEM Limited has appointed Robert Cooper as its new CEO and secured $2.05 million in funding, while progressing key regulatory and technical milestones for its Julia Creek Vanadium and Energy Project.

Avenira Limited has advanced its Wonarah Phosphate Project with Northern Territory Government approval of its Mine Management Plan and secured $7.57 million through a placement to Hebang, while deferring operational start to optimize costs.

Delorean Corporation has marked significant progress in Q4 FY2025, advancing its renewable gas infrastructure and securing crucial regulatory support that could unlock new revenue streams.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Northern Minerals reports strong progress on its Browns Range Heavy Rare Earths Project with key regulatory approvals, promising exploration results, and near-completion of its Definitive Feasibility Study amid tightening global supply.